CTRI/2024/06/069462
Recruiting
未知
Identify microbial and metabolic biomarkers for early detection of Non-alcoholic fatty liver disease (NAFLD) using Gut Function Test (GFT), and to study longitudinal impact of probiotics. - NI
MicrobioTx Health Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: E638- Other specified nutritional deficiencies
- Sponsor
- MicrobioTx Health Private Limited
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Hepatic steatosis with ultrasound elastography or with liver biopsy (Stage 1/2/3/4\)
- •Moderate NAFLD
- •Severe NAFLD without Cirrhosis
- •Severe NAFLD with Cirrhosis
- •All outpatients aged 18\-59 years presenting with NAFLD with various conditions (as described) as per standard definitions belong to any groups above. The diagnosis of NAFLD currently requires: (1\) evidence of hepatic steatosis (HS) by imaging or histology, (2\) no significant alcohol consumption, (3\) no competing causes of HS, and (4\) no coexisting causes of chronic liver disease.
- •Patients who have normal general health and normal findings on clinical history, physical examination, blood count, and have ultrasonographic evidence of fatty liver with no other abnormal clinical or ultrasonographic findings will be included in this study.
- •For NAFLD patients with T2DM \&;/or Obesity, we will recruit
- •a) Patients with a diagnosis of T2DM (International Classification of Diseases (ICD\-11 that was adopted by the 72 nd World Health Assembly in 2019 and will come into effect on 1 st January 2022\) following codes 5A11 which was updated from ICD\-10 codes E11, E11\.0\-E11\.9, E14, and E14\.0\-E14\.9\) as of 31 December 2016 (index date).
Exclusion Criteria
- •Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator
- •Participants with a history of alcohol consumption exceeding 20 grams per day (both male and female)
- •Participants taking immunosuppressants, tamoxifen, amiodarone and/or perhexiline;
- •Currently following a weight loss diet
- •Those who have other known liver diseases (hepatitis viruses A through E, autoimmune disease, Wilson’s disease).
- •Those who are on drugs, which are likely to induce fatty liver or insulin sensitization.
- •Require daytime ventilation assistance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Effectiveness of gut health profile using blood test for patients with Irritable Bowel Syndrome or DepressioCTRI/2024/07/070846MicrobioTx Health Private Limited
Recruiting
Not Applicable
Identification of Biomarkers and Microbiota Specific for Plaque Erosion and Layered Plaque in Patients with Acute Coronary Syndromes: A prospective OCT studyAcute coronary syndromeJPRN-UMIN000047254Massachusetts General Hospital100
Recruiting
Not Applicable
The analysis of the microbiota as biomarkers of response to anticancer drugs in metastatic solid cancersJPRN-UMIN000030778Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.60
Completed
Not Applicable
Analysis of biomarker and microbiome profile and assessment of clinical effectiveness for diagnosis of Chronic PeriodontitisDiseases of the digestive systemKCT0006071Seoul National University Dental Hospital100
Recruiting
Not Applicable
Predictive biomarkers and the role of the microbiome determining response to antiinflammatory treatment in Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis)Crohn's diseaseinflammatory Bowel Diseaseulcerative colitis10017969NL-OMON50413Academisch Medisch Centrum2,240